Candel Therapeutics Progresses Phase 3 Trial for treatment in high-risk localized prostate cancer
Published: 08:58 03 Dec 2024 EST
Candel Therapeutics Chief Medical Officer Garrett Nichols spoke with Steve Darling from Proactive to share updates on the company’s Phase 3 trial investigating an innovative therapeutic approach for patients with intermediate to high-risk localized prostate cancer. The study involves 711 participants randomized in a 2:1 ratio to receive either the experimental therapy or placebo injections, both administered alongside radiotherapy.
The trial aims to achieve a 15% improvement in cure rates by focusing on enhancing disease-free survival and reducing the likelihood of cancer recurrence. Dr. Nichols underscored the pressing need for advancements in prostate cancer care, noting the lack of significant progress in treatments for localized prostate cancer over the last two decades.
“This trial reflects a rigorous and forward-thinking approach that could transform outcomes for these patients,” he stated, highlighting the study’s special protocol assessment with the FDA as a testament to its strong design and regulatory potential.
If successful, the trial could mark a significant breakthrough in prostate cancer treatment, providing a much-needed option for patients with limited alternatives. The therapy aims to improve survival rates and offer renewed hope for individuals facing this complex disease.
